Celldex Therapeutics (CLDX) FCF Margin (2010 - 2026)
Celldex Therapeutics (CLDX) recorded quarterly FCF Margin of 448260.0% in Q1 2026, down 731.63% quarter-over-quarter from 53901.65% in Q4 2025, and down 44039856.0% on a YoY basis from N/an in Q1 2025.
Celldex Therapeutics (CLDX) FCF Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 448260.0% for Q1 2026.
- In Q1 2026, FCF Margin fell 44039856.0% year-over-year to 448260.0%; the TTM figure through Mar 2026 stood at 26127.14% (down 2383382.0% YoY), while the FY2025 annual figure was 13829.06%, down 1155418.0% from the prior year.
- FCF Margin was 448260.0% for Q1 2026 at Celldex Therapeutics, down from 53901.65% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 803.66% in Q4 2023 to a low of 448260.0% in Q1 2026.
- Historically, FCF Margin has averaged 37634.74% across 5 years, with a median of 6996.2% in 2025.
- The sharpest annual moves came in 2025 and 2026: FCF Margin soared 1840907 bps in 2025, then tumbled 44039856 bps in 2026.
- A 5-year view of FCF Margin shows it stood at 1363.73% in 2022, then jumped by 41 bps to 803.66% in 2023, then plunged by 252 bps to 2828.26% in 2024, then tumbled by 1806 bps to 53901.65% in 2025, then sank by 732 bps to 448260.0% in 2026.
- The last three FCF Margin figures came in at 448260.0% (Q1 2026), 53901.65% (Q4 2025), and 6130.96% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Celldex Therapeutics | 2.16 Bn | 2.16 Bn | -1.44 Mn | -448,260.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -448,260.00% |
| Dec 31, 2025 | -53,901.65% |
| Jun 30, 2025 | -6,130.96% |
| Mar 31, 2025 | -7,861.44% |
| Dec 31, 2024 | -2,828.26% |
| Sep 30, 2024 | -1,751.24% |
| Jun 30, 2024 | -1,184.99% |
| Mar 31, 2024 | -26,270.51% |
| Dec 31, 2023 | -803.66% |
| Sep 30, 2023 | -1,262.36% |
| Jun 30, 2023 | -10,300.75% |
| Mar 31, 2023 | -3,014.89% |
| Dec 31, 2022 | -1,363.73% |
| Sep 30, 2022 | -8,731.45% |
| Jun 30, 2022 | -14,059.51% |
| Mar 31, 2022 | -14,430.46% |
| Dec 31, 2021 | -4,454.19% |
| Sep 30, 2021 | -10,821.57% |
| Jun 30, 2021 | -346.93% |
| Mar 31, 2021 | -2,722.77% |